Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05679583

Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer

Pancreatic cancer is a cancer with a poor prognosis and a high mortality rate. The prognosis of surgically resectable pancreatic cancer is better than that of unresectable pancreatic cancer. But the prognosis is still poor enough to report a 2-year disease-free survival rate of 47.0% despite the application of standard treatment. Preoperative chemotherapy or radiotherapy for pancreatic cancer has been performed for a long time, especially for locally advanced pancreatic cancer. However, there are very few studies on the application of preoperative chemotherapy or radiotherapy for borderline resectable or resectable pancreatic cancer. The PREOPANC trial is a representative randomized study to investigate the effect of preoperative chemo/radiation therapy in borderline resectable or resectable pancreatic cancer. As a result, the overall survival, progression-free survival, local control, and distant control rates were significantly superior in preoperative therapy group. However, when only patients with resectable pancreatic cancer were analyzed separately, there was no significant difference in overall survival rate or complete resection rate. In 2020, retrospective propensity score matching analysis using the national cancer database revealed that the addition of preoperative stereotactic body radiation therapy (SBRT) showed a significant increase in overall survival rate rather than preoperative chemotherapy alone. In addition, SBRT also showed a significant increase in overall survival rather than conventional fractionated RT. In summary, the current standard treatment for resectable pancreatic cancer is surgical resection, but a higher survival rate can be expected when preoperative therapy is added. However, there is no study that focused on the role of preoperative SBRT. Therefore, this study aims to confirm the effectiveness of adding preoperative SBRT alone in resectable pancreatic cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Yonsei University Health System, Severance Hospital

Seoul, South Korea

Location status: Recruiting

Location contact

Ik Jae Lee

CONTACT

[email protected]

+82-2-2228-8117

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically diagnosed adenocarcinoma of the pancreas
  • Resectable pancreatic cancer at the time of diagnosis
  • Resectable pancreatic cancer refers to cases in which all of the following conditions are met:
  • If the tumor does not reach the superior mesenteric vein or portal vein, or even if it does, it reaches within 180°
  • If the tumor does not reach the superior mesenteric artery, celiac artery, or common hepatic artery
  • In the absence of distant metastases 3) Patients aged 20 years or older at the time of diagnosis 4) General performance status is 0-2 based on the Eastern Cooperative Oncology Group (ECOG) standard 5) Patients who voluntarily decided to participate in this clinical study and signed the written informed consent

Exclusion criteria

  • If there is a history of radiation exposure to the abdomen
  • Pancreatic cancer that cannot be resected
  • When accompanied by distant metastasis
  • Patients who are currently judged to be difficult to undergo surgery based on general performance status, bone marrow, and kidney function tests
  • Patients with active or uncontrolled infection
  • Patients with uncontrolled heart disease
  • Pregnant or lactating women
  • Patients with a history of malignant tumor excluding skin epithelial carcinoma, except for malignant melanoma, stage 0 cervical cancer, and early thyroid cancer
  • Patients who have been treated for malignant tumors and have been cured for more than 5 years can participate in the study

Treatment and study plan

Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy

Radiation
  • Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.
  • Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.
  • Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX.

Primary outcomes

  1. R0 rate

    Time frame: 2 weeks after the surgical resection

    R0 resection is defined as the resection margin more than 1 mm away from the tumor on histological findings after pancreatic cancer surgery. The R0 rate refers to the proportion of patients showing R0 resection, based on all patients.

Secondary outcomes

  1. Disease-free survival

    Time frame: Patient follow-up will be performed 3 months after the surgery and then at 6-month intervals thereafter. Follow-up will be conducted for a total of 2 years.

    Disease-free survival It is based on the time from the date when pancreatic cancer was first diagnosed histologically to the time when recurrence was confirmed on clinical or radiological examination or when the subject died.

  2. Local control rate

    Time frame: Patient follow-up will be performed 3 months after the surgery and then at 6-month intervals thereafter. Follow-up will be conducted for a total of 2 years.

    Local control rate It is based on the time from the date when pancreatic cancer was first diagnosed histologically to the time when local recurrence was confirmed on clinical and radiological examination.

  3. Overall survival rate

    Time frame: Patient follow-up will be performed 3 months after the surgery and then at 6-month intervals thereafter. Follow-up will be conducted for a total of 2 years.

    Overall survival rate It is based on the date from the date of the first histological diagnosis of pancreatic cancer to the date of death of the subject or the date of the last follow-up.

  4. Treatment related acute/chronic toxicity (based on CTCAE ver 5.0)

    Time frame: Patient follow-up will be performed 3 months after the surgery and then at 6-month intervals thereafter. Follow-up will be conducted for a total of 2 years.

    Treatment related acute/chronic toxicity (based on CTCAE ver 5.0) During treatment, immediately after the end of treatment, 3 months after treatment, and at 6-month intervals thereafter, CTCAE 5.0 is measured.

  5. Quality of life (based on EORTC QLQ-C30)

    Time frame: Patient follow-up will be performed 3 months after the surgery and then at 6-month intervals thereafter. Follow-up will be conducted for a total of 2 years.

    Quality of life (based on EORTC QLQ-C30) Before the start of treatment, immediately after completion, 3 months after treatment, and every 6 months until 2 years thereafter.

  6. Quality of life (based on FACT-Hep)

    Time frame: Patient follow-up will be performed 3 months after the surgery and then at 6-month intervals thereafter. Follow-up will be conducted for a total of 2 years.

    Quality of life (based on FACT-Hep) Before the start of treatment, immediately after completion, 3 months after treatment, and every 6 months until 2 years thereafter.

  7. Tumor recurrence

    Time frame: Patient follow-up will be performed 3 months after the surgery and then at 6-month intervals thereafter. Follow-up will be conducted for a total of 2 years.

    Tumor recurrence Imaging tests and tumor marker tests are performed every 3-6 months after treatment to determine the presence or absence of tumor recurrence.

Study contacts

Contact information is provided by the study sponsor or research team.

Ik Jae Lee

CONTACT

[email protected]

+82-2-2228-8117

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Registry information

Official study title

Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer: A Prospective Phase II Study

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Jan 11, 2023
Registry last updated
Jan 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.